Bladder cancer Avelumab IND Durvalumab Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker. IND Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy IND Enfortumab vedotin Erdafitinib Inbakicept Nivolumab IND Brain cancer Dabrafenib / trametinib Breast cancer Abemaciclib IND Balixafortide Elacestrant Neratinib IND Olaparib IND Paclitaxel Palbociclib IND Pembrolizumab IND Sacituzumab govitecan For adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for advanced disease Eerder behandelde HR+/HER2- gemetastaseerde borstkanker IND Tesetaxel Trastuzumab deruxtecan Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. IND Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or withing 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy. IND Trastuzumab duocarmazine Tucatinib Cervical cancer Cemiplimab IND Lifileucel Colon cancer Eflornithine / sulindac Head and neck cancer Pembrolizumab IND Tislelizumab IND Kidney cancer Cabozantinib IND Ilixadencel Lenvatinib IND Pembrolizumab Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). IND Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. IND Tivozanib IND Liver cancer Atezolizumab IND Durvalumab Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. IND Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC). IND Lenvatinib IND Pembrolizumab IND Tremelimumab IND Lung cancer Adagrasib Amivantamab Atezolizumab IND Avelumab IND Cabozantinib IND Capmatinib Cemiplimab Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. IND Extension of indication to include LIBTAYO in combination with platinum‐based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations, independen of PD-L1 expression. IND Durvalumab Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. IND Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. IND 1L advanced NSCLC IND Completely resected NSCLC IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. IND Ensartinib Lenvatinib IND Lurbinectedin Mobocertinib Nivolumab IND OSE-2101 Pembrolizumab IND Pralsetinib Selpercatinib IND Sintilimab Sotorasib Tepotinib Tislelizumab 2L NSCLC (mono): As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults 1L non-squamous NSCLC (combi): In combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of locally advanced or metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations 1L squamous NSCLC (combi): In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of locally advanced or metastatic squamous NSCLC in adults Toripalimab Trastuzumab deruxtecan IND Tremelimumab Trilaciclib Neuroendocrine cancer Selumetinib Surufatinib Oncology other Afamitresgene autoleucel Dostarlimab Durvalumab IND Efbemalenograstim alfa Erdafitinib Futibatinib Glucarpidase Infigratinib Ivosidenib Jodium (131I) omburtamab Lenvatinib Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation IND Advanced or Recurrent Endometrial Cancer (1L) in combination with pembrolizumab. IND Lipegfilgrastim IND NY-ESO-1 autologous engineered TCR-T cells Nirogacestat Pembrolizumab Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. IND Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1. IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. IND Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. IND indication for treatment with pembrolizumab plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma IND Selinexor IND Sodium thiosulfate Tebentafusp Tislelizumab 2L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma) 1L locally advanced or metastatic ESCC (esophageal squamous-cell carcinoma) Ovarian cancer Dostarlimab IND Mirvetuximab soravtansine Rucaparib IND Prostate cancer Darolutamide IND Degarelix G Enzalutamide IND Gozetotide Leuprolide mesylate Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abiraterone Olaparib IND Pembrolizumab IND Relugolix Talazoparib IND Skin cancer Darleukin fibromun Ipilimumab IND Lenvatinib IND Lifileucel Nivolumab IND Pembrolizumab 1L treatment with pembrolizumab for advanced melanoma, in combination with lenvatinib. IND KEYTRUDA as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection IND Relatlimab / nivolumab Tavokinogene telseplasmid Stomach cancer Catumaxomab Pembrolizumab indication for treatment with pembrolizumab in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) in the treatment of HER2 negative advanced gastric or GEJ adenocarcinoma in adult participants. IND indication for treatment with pembrolizumab plus trastuzumab in combination with standard of care chemotherapy for adults with HER2 positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma IND Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. IND Ripretinib Tislelizumab IND Trastuzumab deruxtecan IND Zolbetuximab Thyroid cancer Cabozantinib IND Pralsetinib Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with Tyrosine Kinase inhibitors and not previously treated with a RET inhibitor. IND Gavreto is indicated for the treatment of adults and pediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with Tyrosine kinase inhibitors and not previously treated with a RET inhibitor. IND Selpercatinib 1L treatment advanced or metastatic RET fusion-positive thyroid cancer (TC) IND Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) IND Tumour agnostic medication Selpercatinib IND